Damora Therapeutics grants 30,350 stock options

Damora Therapeutics, Inc. reported that director Andrew Cheng received a grant of 30,350 stock options on 2026-08-12.

Rhea-AI Filing Summary

Damora Therapeutics, Inc. reported that director Andrew Cheng received a grant of 30,350 stock options on 2026-08-12. The options have an exercise price of $31.00 per share, are exercisable for 30,350 Ordinary Shares, and expire on 2036-08-12. They vest in equal monthly installments through August 12, 2029, subject to his continued service, and this grant brings his directly held option position to 30,350 derivative securities.

Insider Trade Summary

Grant/Award: 30,350 shares

Grant/Award 1 txn

Insider Cheng Andrew

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	30,350	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 30,350 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Options Granted: 30,350 options Exercise Price: $31.00 per share Expiration Date: 2036-08-12 +3 more

6 metrics

Options Granted 30,350 options Stock Option (right to buy) grant on 2026-08-12

Exercise Price $31.00 per share Conversion or exercise price of granted options

Expiration Date 2036-08-12 Option term for stock option grant

Underlying Shares 30,350 shares Ordinary Shares underlying the stock options

Post-transaction derivative holdings 30,350 options Total derivative securities owned following the grant

Vesting End Date 2029-08-12 Equal monthly vesting through this date, subject to continued service

Key Terms

Stock Option (right to buy, derivative securities, exercise price, vesting

4 terms

Stock Option (right to buy financial

"security_title: Stock Option (right to buy)"

derivative securities financial

"brings his directly held option position to 30,350 derivative securities"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

exercise price financial

"conversion_or_exercise_price: 31.0000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option will vest in equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Andrew Cheng acquire in Damora Therapeutics (DMRA) according to this Form 4?

Andrew Cheng received a grant of 30,350 stock options to purchase Damora Therapeutics Ordinary Shares at an exercise price of $31.00 per share, all reported as directly owned derivative securities.

What is the vesting schedule of Andrew Cheng’s new DMRA stock options?

The 30,350 stock options vest in equal monthly installments through August 12, 2029, conditioned on Andrew Cheng’s continued service to Damora Therapeutics on each vesting date.

What is the exercise price and expiration date of Andrew Cheng’s DMRA options?

The granted options carry an exercise price of $31.00 per share and an expiration date of August 12, 2036, providing a long-term right to purchase Ordinary Shares of Damora Therapeutics.

How many Damora Therapeutics derivative securities does Andrew Cheng hold after this transaction?

Following the grant, Andrew Cheng beneficially owns 30,350 derivative securities directly, all represented by stock options exercisable for 30,350 Ordinary Shares of Damora Therapeutics.

Was Andrew Cheng’s DMRA option grant made under a Rule 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked as affirmative, and there is no footnote stating these options were granted pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 05:00 PM Accepted by SEC EDGAR 08/13/2026 - 05:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cheng Andrew

(Last) (First) (Middle)

C/O DAMORA THERAPEUTICS, INC.

221 CRESCENT ST., BLDG 23, STE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Damora Therapeutics, Inc. [ DMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$31	08/12/2026		A		30,350		(1)	08/12/2036	Ordinary Shares	30,350	$0	30,350	D

Explanation of Responses:

1. This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

	/s/ Garrett Winslow	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)